The "Lazarus Response" in Treatment-Naive, Poor Performance Status Patients With Non-Small-Cell Lung Cancer and Epidermal Growth Factor Receptor Mutation

被引：51

作者：

Langer, Corey J. ^{[1
]}

机构：

[1] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 09期

关键词：

PHASE-III TRIAL; PACLITAXEL POLIGLUMEX CT-2103; SINGLE-AGENT GEMCITABINE; PS; PATIENTS; 1ST-LINE GEFITINIB; PLUS CARBOPLATIN; RANDOMIZED TRIAL; CHEMOTHERAPY; ERLOTINIB; COMBINATION;

D O I：

10.1200/JCO.2008.20.4859

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：1350 / 1354

页数：5

共 42 条

[31]

PIRKER R, 2008, J CLIN ONCOL S, V26, pS1006

[32]

Rosell Rafael, 2007, Future Oncol, V3, P277, DOI 10.2217/14796694.3.3.277

[33] A RANDOMIZED TRIAL OF THE 4 MOST ACTIVE REGIMENS FOR METASTATIC NON SMALL-CELL LUNG-CANCER [J].

RUCKDESCHEL, JC ;

FINKELSTEIN, DM ;

ETTINGER, DS ;

CREECH, RH ;

MASON, BA ;

JOSS, RA ;

VOGL, S .

JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (01) :14-22

[34] Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer [J].

Schiller, JH ;

Harrington, D ;

Belani, CP ;

Langer, C ;

Sandler, A ;

Krook, J ;

Zhu, JM ;

Johnson, DH .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (02) :92-98

[35] Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer:: The Swedish Lung Cancer Study Group [J].

Sederholm, C ;

Hillerdal, G ;

Lamberg, K ;

Kölbeck, K ;

Dufmats, M ;

Westberg, R ;

Gawande, SR .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (33) :8380-8388

[36] First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations [J].

Sequist, Lecia V. ;

Martins, Renato G. ;

Spigel, David ;

Grunberg, Steven M. ;

Spira, Alexander ;

Jaenne, Pasi A. ;

Joshi, Victoria A. ;

McCollum, David ;

Evans, Tracey L. ;

Muzikansky, Alona ;

Kuhlmann, Georgiana L. ;

Han, Moon ;

Goldberg, Jonathan S. ;

Settleman, Jeffrey ;

Iafrate, A. John ;

Engelman, Jeffrey A. ;

Haber, Daniel A. ;

Johnson, Bruce E. ;

Lynch, Thomas J. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15) :2442-2449

[37] Erlotinib in previously treated non-small-cell lung cancer [J].

Shepherd, FA ;

Pereira, JR ;

Ciuleanu, T ;

Tan, EH ;

Hirsh, V ;

Thongprasert, S ;

Campos, D ;

Maoleekoonpiroj, S ;

Smylie, M ;

Martins, R ;

van Kooten, M ;

Dediu, M ;

Findlay, B ;

Tu, DS ;

Johnston, D ;

Bezjak, A ;

Clark, G ;

Santabárbara, P ;

Seymour, L .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (02) :123-132

[38]

SHIGEMATSU H, 2005, J NATL CANC I, V97

[39] Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: A multicohort cross-institutional study [J].

Taguchi, Fumiko ;

Solomon, Benjamin ;

Gregorc, Vanesa ;

Roder, Heinrich ;

Gray, Robert ;

Kasahara, Kazuo ;

Nishio, Makoto ;

Brahmer, Julie ;

Spreafico, Anna ;

Ludovini, Vienna ;

Massion, Pierre P. ;

Dziadziuszko, Rafal ;

Schiller, Joan ;

Grigorieva, Julia ;

Tsypin, Maxim ;

Hunsucker, Stephen W. ;

Caprioli, Richard ;

Duncan, Mark W. ;

Hirsch, Fred R. ;

Bunn, Paul A., Jr. ;

Carbone, David P. .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2007, 99 (11) :838-846

[40] Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) [J].

Thatcher, N ;

Chang, A ;

Parikh, P ;

Pereira, JR ;

Ciuleanu, T ;

von Pawel, J ;

Thongprasert, S ;

Tan, EH ;

Pemberton, K ;

Archer, V ;

Carroll, K .

LANCET, 2005, 366 (9496) :1527-1537

← 1 2 3 4 5 →